The mathematics of cancer: Integrating quantitative models

Nature Reviews Cancer

Volumn 15, Issue 12, 2015, Pages 730-745

  Altrock, Philipp M ^a,b   Liu, Lin L ^a   Michor, Franziska ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IBRUTINIB; INTERLEUKIN 21; VEMURAFENIB;

ANTIANDROGEN THERAPY; BRAIN TUMOR; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CARCINOGENESIS; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; GLIOBLASTOMA; GLYCOLYSIS; HETEROZYGOSITY LOSS; HUMAN; LEUKEMIA; MATHEMATICAL MODEL; METASTASIS; MUTATION; NATURAL KILLER CELL; NEOPLASM; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; DISEASE COURSE; NEOPLASMS; PROGNOSIS; THEORETICAL MODEL;

ANIMALS; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NEOPLASMS; PROGNOSIS;

EID: 84948685988     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc4029     Document Type: Review

References (218)

1. Weinberg, R. A. The Biology of Cancer (Garland Science, (2013).
2. Vogelstein, B. & Kinzler, K. W. The Genetic Basis of Human Cancer (McGraw-Hill, 1998).
3. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
4. Armitage, P. & Doll, R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 8, 1-12 (1954).
5. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
6. Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17-37 (2013).
7. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).
8. Pages, F. et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666 (2005).
9. Allan, J. M. & Travis, L. B. Mechanisms of therapy-related carcinogenesis. Nat. Rev. Cancer 5, 943-955 (2005).
10. Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284 (2009).
11. Kim, M. Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326 (2009).
12. Anderson, A. R., Weaver, A. M., Cummings, P. T. & Quaranta, V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127, 905-915 (2006). A multiscale mathematical model that attempts to describe cancer evolution and the dynamics of the microenvironment, and shows that both genetic changes and environmental changes can impact cancer invasiveness.
13. Vaupel, P., Kallinowski, F. & Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49, 6449-6465 (1989).
14. Anderson, A. R. & Quaranta, V. Integrative mathematical oncology. Nat. Rev. Cancer 8, 227-234 (2008).
15. Byrne, H. M. Dissecting cancer through mathematics: from the cell to the animal model. Nat. Rev. Cancer 10, 221-230 (2010).
16. Knudson, A. G. Jr Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820-823 (1971).
17. Cavenee, W. K. et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305, 779-784 (1983).
18. Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747 (2013). A stochastic evolutionary model that identifies probabilities of evolution of resistance to combination therapy.
19. Lenaerts, T., Pacheco, J. M., Traulsen, A. & Dingli, D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica 95, 900-907 (2010).
20. Diaz, L. A. Jr et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
21. Jones, S. et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA 105, 4283-4288 (2008).
22. Leder, K. et al. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell 156, 603-616 (2014). A mathematical model and optimization approach to identify better radiation scheduling in glioblastoma that led to survival improvement in a mouse trial.
23. Sherratt, J. A. & Nowak, M. A. Oncogenes, anti-oncogenes and the immune response to cancer: a mathematical model. Proc. Biol. Sci. 248, 261-271 (1992).
24. Komarova, N. L. & Wodarz, D. Drug resistance in cancer: principles of emergence and prevention. Proc. Natl Acad. Sci. USA 102, 9714-9719 (2005). A mathematical modelling contribution towards the understanding of resistance that existed prior to chemotherapy and targeted combination therapy.
25. Sanga, S. et al. Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev. Anticancer Ther. 6, 1361-1376 (2006).
26. Swanson, K. R., Alvord, E. C. Jr & Murray, J. D. Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. Br. J. Cancer 86, 14-18 (2002). A hallmark paper that shows how a virtual tumour allows data-driven therapy improvements using mathematical modelling.
27. Frank, S. A., Iwasa, Y. & Nowak, M. A. Patterns of cell division and the risk of cancer. Genetics 163, 1527-1532 (2003).
28. Armitage, P. & Doll, R. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br. J. Cancer 11, 161-169 (1957).
29. Nordling, C. O. A new theory on cancer-inducing mechanism. Br. J. Cancer 7, 68-72 (1953).
30. Fisher, J. & Hollomon, J. A hypothesis for the origin of cancer foci. Cancer 4, 916-918 (1951).
31. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719-724 (2009).
32. Foy, M., Spitz, M. R., Kimmel, M. & Gorlova, O. Y. A smoking-based carcinogenesis model for lung cancer risk prediction. Int. J. Cancer 129, 1907-1913 (2011).
33. Kimmel, M. & Axelrod, D. Branching Processes in Biology. Interdisciplinary Applied Mathematics (Springer, 2015).
34. Haccou, P. Branching Processes: Variation, Growth, and Extinction of Populations (Cambridge Univ. Press, 2005).
35. Durrett, R. Branching Process Models of Cancer (Springer, 2015).
36. Antal, T. & Krapivsky, P. L. Exact solution of a two-type branching process: models of tumor progression. J. Statist. Mechan.-Theory Exper. (2011).
37. Parzen, E. Stochastic processes (SIAM, 1999).
38. Bozic, I. et al. Accumulation of driver and passenger mutations during tumor progression. Proc. Natl Acad. Sci. USA 107, 18545-18550 (2010). A mathematical modelling contribution that studies the accumulation of driver and passenger mutations in cancer.
39. Bauer, B., Siebert, R. & Traulsen, A. Cancer initiation with epistatic interactions between driver and passenger mutations. J. Theor. Biol. 358, 52-60 (2014).
40. Tomasetti, C., Vogelstein, B. & Parmigiani, G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc. Natl Acad. Sci. USA 110, 1999-2004 (2013). A mathematical model of development and tumorigenesis in which driver and passenger mutations accumulate.
41. Tomasetti, C. & Vogelstein, B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78-81 (2015).
42. Wodarz, D. & Zauber, A. G. Cancer: risk factors and random chances. Nature 517, 563-564 (2015).
43. Ashford, N. A. et al. Cancer risk: role of environment. Science 347, 727 (2015).
44. OCallaghan, M. Cancer risk: accuracy of literature. Science 347, 729 (2015).
45. Potter, J. D. & Prentice, R. L. Cancer risk: tumors excluded. Science 347, 727 (2015).
46. Tomasetti, C. & Vogelstein, B. Cancer risk: role of environment-response. Science 347, 729-731 (2015).
47. Noble, R., Kaltz, O. & Hochberg, M. E. Petos paradox and human cancers. Phil. Trans. R. Soc. B 370, 11 (2015).
48. McFarland, C. D., Korolev, K. S., Kryukov, G. V., Sunyaev, S. R. & Mirny, L. A. Impact of deleterious passenger mutations on cancer progression. Proc. Natl Acad. Sci. USA 110, 2910-2915 (2013). A mathematical model that includes slightly deleterious passenger mutations that accumulate between sweeps caused by oncogenic driver mutations.
49. McFarland, C. D., Mirny, L. A. & Korolev, K. S. Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. Proc. Natl Acad. Sci. USA 111, 15138-15143 (2014).
50. Foo, J., Leder, K. & Michor, F. Stochastic dynamics of cancer initiation. Phys. Biol. 8, 015002 (2011).
51. Moran, P. A. P. Random processes in genetics. Math. Proc. Cambridge Phil. Soc. 54, 60-71 (1958).
52. Foo, J. et al. An evolutionary approach for identifying driver mutations in colorectal cancer. PLoS Comput. Biol. 11, e1004350 (2015).
53. Mumenthaler, S. M. et al. The impact of microenvironmental heterogeneity on the evolution of drug resistance in cancer cells. Cancer Inform. 14, 19-31 (2015).
54. Beerenwinkel, N. et al. Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 3, e225 (2007). A mathematical model that allows calculation of the expected waiting time to cancer using a Wright-Fisher process and tumour mutation data.
55. Werner, B., Dingli, D. & Traulsen, A. A deterministic model for the occurrence and dynamics of multiple mutations in hierarchically organized tissues. J. R. Soc. Interface 10, 20130349 (2013).
56. Werner, B., Dingli, D., Lenaerts, T., Pacheco, J. M. & Traulsen, A. Dynamics of mutant cells in hierarchical organized tissues. PLoS Comput. Biol. 7, e1002290 (2011).
57. Weekes, S. L. et al. A multicompartment mathematical model of cancer stem cell-driven tumor growth dynamics. Bull. Math. Biol. 76, 1762-1782 (2014).
58. Michor, F., Nowak, M. A., Frank, S. A. & Iwasa, Y. Stochastic elimination of cancer cells. Proc. Biol. Sci. 270, 2017-2024 (2003).
59. Roeder, I. et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 12, 1181-1184 (2006).
60. Haeno, H., Levine, R. L., Gilliland, D. G. & Michor, F. A progenitor cell origin of myeloid malignancies. Proc. Natl Acad. Sci. USA 106, 16616-16621 (2009). Mathematical modelling of the different evolutionary pathways leading to cancer, which calculates the likelihood of individual cell types serving as the cell of origin.
61. Ganguly, R. & Puri, I. K. Mathematical model for the cancer stem cell hypothesis. Cell Prolif. 39, 3-14 (2006).
62. Hambardzumyan, D., Cheng, Y. K., Haeno, H., Holland, E. C. & Michor, F. The probable cell of origin of NF1- and PDGF-driven glioblastomas. PLoS ONE 6, e24454 (2011).
63. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
64. Vogelstein, B. & Kinzler, K. W. The Genetic Basis of Human Cancer (McGraw, 2002).
65. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532 (1988).
66. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
67. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
68. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
69. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
70. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
71. International Cancer Genome Consortium et al. International network of cancer genome projects. Nature 464, 993-998 (2010).
72. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
73. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
74. Desper, R. et al. Inferring tree models for oncogenesis from comparative genome hybridization data. J. Comput. Biol. 6, 37-51 (1999).
75. Desper, R. et al. Distance-based reconstruction of tree models for oncogenesis. J. Comput. Biol. 7, 789-803 (2000).
76. Hoglund, M., Frigyesi, A., Sall, T., Gisselsson, D. & Mitelman, F. Statistical behavior of complex cancer karyotypes. Genes Chromosomes Cancer 42, 327-341 (2005).
77. Beerenwinkel, N. et al. Learning multiple evolutionary pathways from cross-sectional data. J. Comput. Biol. 12, 584-598 (2005). The introduction of a mixture model of multiple evolutionary trees that allows detailed characterization of mutations leading to cancer.
78. Huang, Z. et al. Construction of tree models for pathogenesis of nasopharyngeal carcinoma. Genes Chromosomes Cancer 40, 307-315 (2004).
79. Pathare, S., Schaffer, A. A., Beerenwinkel, N. & Mahimkar, M. Construction of oncogenetic tree models reveals multiple pathways of oral cancer progression. Int. J. Cancer 124, 2864-2871 (2009).
80. Hjelm, M., Hoglund, M. & Lagergren, J. New probabilistic network models and algorithms for oncogenesis. J. Comput. Biol. 13, 853-865 (2006).
81. Gerstung, M., Baudis, M., Moch, H. & Beerenwinkel, N. Quantifying cancer progression with conjunctive Bayesian networks. Bioinformatics 25, 2809-2815 (2009).
82. Simon, R. et al. Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis. Genes Chromosomes Cancer 28, 106-120 (2000).
83. Gerstung, M., Eriksson, N., Lin, J., Vogelstein, B. & Beerenwinkel, N. The temporal order of genetic and pathway alterations in tumorigenesis. PLoS ONE 6, e27136 (2011).
84. Attolini, C. S. et al. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc. Natl Acad. Sci. USA 107, 17604-17609 (2010). The introduction of an evolutionary modelling approach allowing the identification of the order of mutations fuelling tumour development.
85. Cheng, Y. K. et al. A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput. Biol. 8, e1002337 (2012).
86. Antal, T. & Scheuring, I. Fixation of strategies for an evolutionary game in finite populations. Bull. Math. Biol. 68, 1923-1944 (2006).
87. Li, X. et al. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barretts esophagus. Cancer Prev. Res. (Phila) 7, 114-127 (2014).
88. Sprouffske, K., Pepper, J. W. & Maley, C. C. Accurate reconstruction of the temporal order of mutations in neoplastic progression. Cancer Prev. Res. (Phila) 4, 1135-1144 (2011).
89. Wang, Y. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512, 155-160 (2014).
90. Martins, F. C. et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2, 503-511 (2012).
91. Durinck, S. et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov. 1, 137-143 (2011).
92. Greenman, C. D. et al. Estimation of rearrangement phylogeny for cancer genomes. Genome Res. 22, 346-361 (2012).
93. Purdom, E. et al. Methods and challenges in timing chromosomal abnormalities within cancer samples. Bioinformatics 29, 3113-3120 (2013).
94. Sottoriva, A. et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47, 209-216 (2015).
95. Fidler, I. J. The pathogenesis of cancer metastasis: the seed and soil hypothesis revisited. Nat. Rev. Cancer 3, 453-458 (2003).
96. Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature 411, 375-379 (2001).
97. Mueller, M. M. & Fusenig, N. E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4, 839-849 (2004).
98. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98-101 (1989).
99. Byrne, H. M. & Chaplain, M. Growth of necrotic tumors in the presence and absence of inhibitors. Math. Biosci. 135, 187-216 (1996).
100. Sherratt, J. A. & Chaplain, M. A. A new mathematical model for avascular tumour growth. J. Math. Biol. 43, 291-312 (2001).
101. Ferreira, S. C. Jr., Martins, M. L. & Vilela, M. J. Reaction-diffusion model for the growth of avascular tumor. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 65, 021907 (2002).
102. Orme, M. E. & Chaplain, M. A. Two-dimensional models of tumour angiogenesis and anti-angiogenesis strategies. IMA J. Math. Appl. Med. Biol. 14, 189-205 (1997).
103. Stokes, C. L. & Lauffenburger, D. A. Analysis of the roles of microvessel endothelial cell random motility and chemotaxis in angiogenesis. J. Theor. Biol. 152, 377-403 (1991).
104. Macklin, P. et al. Multiscale modelling and nonlinear simulation of vascular tumour growth. J. Math. Biol. 58, 765-798 (2009).
105. Rejniak, K. A. & Anderson, A. R. Hybrid models of tumor growth. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 115-125 (2011).
106. Hatzikirou, H., Basanta, D., Simon, M., Schaller, K. & Deutsch, A. Go or grow: the key to the emergence of invasion in tumour progression? Math. Med. Biol. 29, 49-65 (2012).
107. Anderson, A. R. & Chaplain, M. A. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull. Math. Biol. 60, 857-899 (1998).
108. McDougall, S. R., Anderson, A. R. & Chaplain, M. A. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J. Theor. Biol. 241, 564-589 (2006).
109. Kim, Y., Stolarska, M. A. & Othmer, H. G. A hybrid model for tumor spheroid growth in vitro I: theoretical development and early results. Math. Models Methods Appl. Sci. 17, 1773-1798 (2007).
110. Anderson, A. R. A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Math. Med. Biol. 22, 163-186 (2005). One of the first papers to use multiscale hybrid models in cancer.
111. Araujo, A., Cook, L. M., Lynch, C. C. & Basanta, D. An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. Cancer Res. 74, 2391-2401 (2014).
112. Li, X. et al. Nonlinear three-dimensional simulation of solid tumor growth. Discrete Continuous Dyn. Sys. Ser. B 7, 581-604 (2007).
113. Frieboes, H. B. et al. Three-dimensional multispecies nonlinear tumor growth-II: tumor invasion and angiogenesis. J. Theor. Biol. 264, 1254-1278 (2010).
114. Wise, S. M., Lowengrub, J. S., Frieboes, H. B. & Cristini, V. Three-dimensional multispecies nonlinear tumor growth-I Model and numerical method. J. Theor. Biol. 253, 524-543 (2008).
115. Frieboes, H. B. et al. Prediction of drug response in breast cancer using integrative experimental/ computational modeling. Cancer Res. 69, 4484-4492 (2009).
116. Waclaw, B. et al. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature (2015). A model that combines spatially explicit evolutionary processes with dynamics of mutation accumulation.
117. Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519-530 (1927).
118. Gatenby, R. A. & Gawlinski, E. T. A reaction-diffusion model of cancer invasion. Cancer Res. 56, 5745-5753 (1996).
119. Patel, A. A., Gawlinski, E. T., Lemieux, S. K. & Gatenby, R. A. A cellular automaton model of early tumor growth and invasion. J. Theor. Biol. 213, 315-331 (2001).
120. Gerlee, P. & Anderson, A. R. A hybrid cellular automaton model of clonal evolution in cancer: the emergence of the glycolytic phenotype. J. Theor. Biol. 250, 705-722 (2008).
121. Swanson, K. R., Bridge, C., Murray, J. & Alvord Jr, E. C. Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J. Neurol. Sci. 216, 1-10 (2003).
122. Cocosco, C. A., Kollokian, V., Kwan, R. K.-S., Pike, G. B. & Evans, A. C. BrainWeb: online interface to a 3D MRI simulated brain database. NeuroImage 5, S425 (1997).
123. Harpold, H. L., Alvord, E. C. Jr & Swanson, K. R. The evolution of mathematical modeling of glioma proliferation and invasion. J. Neuropathol. Exp. Neurol. 66, 1-9 (2007).
124. Wang, C. H. et al. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Res. 69, 9133-9140 (2009).
125. Swanson, K. R. et al. Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology. Cancer Res. 71, 7366-7375 (2011).
126. Atuegwu, N. C. et al. Incorporation of diffusion-weighted magnetic resonance imaging data into a simple mathematical model of tumor growth. Phys. Med. Biol. 57, 225-240 (2012).
127. Yankeelov, T. E. et al. Clinically relevant modeling of tumor growth and treatment response. Sci. Transl Med. 5, 187ps9 (2013).
128. Yankeelov, T. E., Quaranta, V., Evans, K. J. & Rericha, E. C. Toward a science of tumor forecasting for clinical oncology. Cancer Res. 75, 918-923 (2015).
129. Deming, D. A. et al. PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene 33, 2245-2254 (2014).
130. Mahabeleshwar, G. H., Feng, W., Reddy, K., Plow, E. F. & Byzova, T. V. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ. Res. 101, 570-580 (2007).
131. Archetti, M., Ferraro, D. A. & Christofori, G. Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer. Proc. Natl Acad. Sci. USA 112, 1833-1838 (2015).
132. Gerlee, P. & Altrock, P. M. Complexity and stability in growing cancer cell populations. Proc. Natl Acad. Sci. USA 112, E2742-E2743 (2015).
133. Marusyk, A. et al. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514, 54-58 (2014).
134. Enderling, H., Hlatky, L. & Hahnfeldt, P. Migration rules: tumours are conglomerates of self-metastases. Br. J. Cancer 100, 1917-1925 (2009).
135. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
136. Chapman, S. J., Shipley, R. J. & Jawad, R. Multiscale modeling of fluid transport in tumors. Bull. Math. Biol. 70, 2334-2357 (2008).
137. Chaplain, M. A., McDougall, S. R. & Anderson, A. R. Mathematical modeling of tumor-induced angiogenesis. Annu. Rev. Biomed. Eng. 8, 233-257 (2006).
138. Alarcon, T., Byrne, H. M. & Maini, P. K. A multiple scale model for tumor growth. Multiscale Model. Simul. 3, 440-475 (2005).
139. Rockne, R. et al. Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. Phys. Med. Biol. 55, 3271-3285 (2010).
140. Jackson, T., Komarova, N. & Swanson, K. R. Mathematical oncology: using mathematics to enable cancer discoveries. Am. Math. Mon. 121, 840-856 (2014).
141. Dale, R. G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br. J. Radiol 58, 515-528 (1985).
142. Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
143. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl Med. 3, 95ra73 (2011).
144. Blattman, J. N. & Greenberg, P. D. Cancer immunotherapy: a treatment for the masses. Science 305, 200-205 (2004).
145. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
146. Old, L. J. Cancer immunology: the search for specificity-G. H. A. Clowes Memorial lecture. Cancer Res. 41, 361-375 (1981).
147. Abbas, A. K., Lichtman, A. H. & Pillai, S. Cellular and Molecular Immunology (Elsevier Health Sciences, 1994).
148. Kuznetsov, V. in A Survey of Models for Tumor-Immune System Dynamics (eds Adam, J. A. & Bellomo, N.) 237-294 (Springer, 1997).
149. Bellomo, N. & Preziosi, L. Modelling and mathematical problems related to tumor evolution and its interaction with the immune system. Math. Computer Modell. 32, 413-452 (2000).
150. Kolev, M. Mathematical modelling of the competition between tumors and immune system considering the role of the antibodies. Math. Computer Modell. 37, 1143-1152 (2003).
151. de Pillis, L. G. & Radunskaya, A. A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. Computat. Math. Methods Med. 3, 79-100 (2001).
152. de Pillis, L. G., Radunskaya, A. E. & Wiseman, C. L. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 65, 7950-7958 (2005).
153. dOnofrio, A. Metamodeling tumor-immune system interaction, tumor evasion and immunotherapy. Math. Computer Modell. 47, 614-637 (2008).
154. dOnofrio, A. A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Phys. D Nonlin. Phenomena 208, 220-235 (2005).
155. Sivakumar, P. V., Foster, D. C. & Clegg, C. H. Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses. Immunology 112, 177-182 (2004).
156. Cappuccio, A., Elishmereni, M. & Agur, Z. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res. 66, 7293-7300 (2006).
157. Pappalardo, F. et al. SimB16: modeling induced immune system response against B16-melanoma. PLoS ONE 6, e26523 (2011).
158. Pienta, K. J., Robertson, B. A., Coffey, D. S. & Taichman, R. S. The cancer diaspora: metastasis beyond the seed and soil hypothesis. Clin. Cancer Res. 19, 5849-5855 (2013).
159. Comen, E. & Norton, L. Self-seeding in cancer. Recent Results Cancer Res. 195, 13-23 (2012).
160. Saidel, G. M., Liotta, L. A. & Kleinerman, J. System dynamics of metastatic process from an implanted tumor. J. Theor. Biol. 56, 417-434 (1976).
161. Panetta, J. C. A mathematical model of periodically pulsed chemotherapy: tumor recurrence and metastasis in a competitive environment. Bull. Math. Biol. 58, 425-447 (1996).
162. Enderling, H. et al. Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. Cancer Res. 69, 8814-8821 (2009). A modelling contribution that combines concepts of a differentiation hierarchy with spatial cell migration and therapy effects.
163. Almendro, V. et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 74, 1338-1348 (2014).
164. Scott, J., Kuhn, P. & Anderson, A. R. Unifying metastasis - integrating intravasation, circulation and end-organ colonization. Nat. Rev. Cancer 12, 445-446 (2012).
165. Weiss, L. Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin. Exp. Metastasis 10, 191-199 (1992).
166. Scott, J. G., Basanta, D., Anderson, A. R. & Gerlee, P. A mathematical model of tumour self-seeding reveals secondary metastatic deposits as drivers of primary tumour growth. J. R. Soc. Interface 10, 20130011 (2013).
167. Scott, J. G., Fletcher, A. G., Maini, P. K., Anderson, A. R. & Gerlee, P. A filter-flow perspective of haematogenous metastasis offers a non-genetic paradigm for personalised cancer therapy. Eur. J. Cancer 50, 3068-3075 (2014).
168. Fu, F., Nowak, M. A. & Bonhoeffer, S. Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput. Biol. 11, e1004142 (2015).
169. Haeno, H. et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148, 362-375 (2012). A stochastic process model that considers tumour growth, death, mutation and dissemination events parameterized using pancreatic cancer patient data to identify improved treatment strategies.
170. Haeno, H. & Michor, F. The evolution of tumor metastases during clonal expansion. J. Theor. Biol. 263, 30-44 (2010).
171. Newton, P. K. et al. A stochastic Markov chain model to describe lung cancer growth and metastasis. PLoS ONE 7, e34637 (2012).
172. Newton, P. K. et al. Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. Cancer Res. 73, 2760-2769 (2013). A mathematical model parameterized using tumour autopsy data to study the metastatic process, which allows different tumour sites to be classified as spreaders or sponges.
173. Bretcha-Boix, P., Rami-Porta, R., Mateu-Navarro, M., Hoyuela-Alonso, C. & Marco-Molina, C. Surgical treatment of lung cancer with adrenal metastasis. Lung Cancer 27, 101-105 (2000).
174. Bazhenova, L. et al. Adrenal metastases in lung cancer: clinical implications of a mathematical model. J. Thorac. Oncol. 9, 442-446 (2014).
175. Pathak, A. & Kumar, S. Independent regulation of tumor cell migration by matrix stiffness and confinement. Proc. Natl Acad. Sci. USA 109, 10334-10339 (2012).
176. Michor, F., Liphardt, J., Ferrari, M. & Widom, J. What does physics have to do with cancer? Nat. Rev. Cancer 11, 657-670 (2011).
177. Jain, R. K., Tong, R. T. & Munn, L. L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67, 2729-2735 (2007).
178. Jain, R. K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205-2218 (2013).
179. Coldman, A. J. & Goldie, J. H. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull. Math. Biol. 48, 279-292 (1986).
180. Goldie, J. H. & Coldman, A. J. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat. Rep. 67, 923-931 (1983).
181. Goldie, J. H. & Coldman, A. J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 44, 3643-3653 (1984).
182. Norton, L. & Simon, R. Growth curve of an experimental solid tumor following radiotherapy. J. Natl Cancer Inst. 58, 1735-1741 (1977).
183. Citron, M. L. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439 (2003).
184. Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727-1733 (1979).
185. Bonadonna, G., Zambetti, M., Moliterni, A., Gianni, L. & Valagussa, P. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J. Clin. Oncol. 22, 1614-1620 (2004).
186. Foo, J. & Michor, F. Evolution of acquired resistance to anti-cancer therapy. J. Theor. Biol. 355, 10-20 (2014).
187. Foo, J. & Michor, F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput. Biol. 5, e1000557 (2009).
188. Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl Med. 3, 90ra59 (2011). An evolutionary mathematical model that identifies optimum dosing strategies of targeted drugs to delay the emergence of resistance.
189. Foo, J., Chmielecki, J., Pao, W. & Michor, F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J. Thorac. Oncol. 7, 1583-1593 (2012).
190. Michor, F. et al. Dynamics of chronic myeloid leukaemia. Nature 435, 1267-1270 (2005).
191. Neal, M. L. et al. Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. Cancer Res. 73, 2976-2986 (2013).
192. Corwin, D. et al. Toward patient-specific, biologically optimized radiation therapy plans for the treatment of glioblastoma. PLoS ONE 8, e79115 (2013).
193. Jain, H. V., Clinton, S. K., Bhinder, A. & Friedman, A. Mathematical modeling of prostate cancer progression in response to androgen ablation therapy. Proc. Natl Acad. Sci. USA 108, 19701-19706 (2011).
194. Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894-4903 (2009). A mathematical model that suggests that outcomes can be improved by maintaining a stable tumour burden in which resistant tumour cells are suppressed by sensitive cells.
195. Gatenby, R. A. & Frieden, B. R. Inducing catastrophe in malignant growth. Math. Med. Biol. 25, 267-283 (2008).
196. Luria, S. E. & Delbruck, M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28, 491-511 (1943).
197. Frank, S. A. Somatic mosaicism and cancer: inference based on a conditional Luria-Delbruck distribution. J. Theor. Biol. 223, 405-412 (2003).
198. Haeno, H., Iwasa, Y. & Michor, F. The evolution of two mutations during clonal expansion. Genetics 177, 2209-2221 (2007).
199. Durrett, R. & Moseley, S. Evolution of resistance and progression to disease during clonal expansion of cancer. Theor. Popul. Biol. 77, 42-48 (2010).
200. Iwasa, Y., Michor, F. & Nowak, M. A. Evolutionary dynamics of escape from biomedical intervention. Proc. Biol. Sci. 270, 2573-2578 (2003).
201. Komarova, N. L. & Wodarz, D. Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theor. Popul. Biol. 72, 523-538 (2007).
202. Bozic, I. & Nowak, M. A. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc. Natl Acad. Sci. USA 111, 15964-15968 (2014).
203. Mumenthaler, S. M. et al. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol. Pharm. 8, 2069-2079 (2011).
204. Komarova, N. Stochastic modeling of drug resistance in cancer. J. Theor. Biol. 239, 351-366 (2006).
205. Komarova, N. L., Burger, J. A. & Wodarz, D. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc. Natl Acad. Sci. USA 111, 13906-13911 (2014).
206. Altrock, P. M. & Traulsen, A. Deterministic evolutionary game dynamics in finite populations. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 80, 011909 (2009).
207. Werner, B., Lutz, D., Brummendorf, T. H., Traulsen, A. & Balabanov, S. Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data. PLoS ONE 6, e28955 (2011).
208. Gallaher, J. & Anderson, A. R. Evolution of intratumoral phenotypic heterogeneity: the role of trait inheritance. Interface Focus 3, 20130016 (2013).
209. Huang, W., Haubold, B., Hauert, C. & Traulsen, A. Emergence of stable polymorphisms driven by evolutionary games between mutants. Nat. Commun. 3, 919 (2012).
210. Huang, W., Hauert, C. & Traulsen, A. Stochastic game dynamics under demographic fluctuations. Proc. Natl Acad. Sci. USA 112, 9064-9069 (2015).
211. Archetti, M., Ferraro, D. A. & Christofori, G. Reply to Gerlee and Altrock: diffusion and population size in game theory models of cancer. Proc. Natl Acad. Sci. USA 112, E2744 (2015).
212. Tabassum, D. P. & Polyak, K. Tumorigenesis: it takes a village. Nat. Rev. Cancer 15, 473-483 (2015).
213. Pacheco, J. M., Santos, F. C. & Dingli, D. The ecology of cancer from an evolutionary game theory perspective. Interface Focus 4, 20140019 (2014).
214. Axelrod, R., Axelrod, D. E. & Pienta, K. J. Evolution of cooperation among tumor cells. Proc. Natl Acad. Sci. USA 103, 13474-13479 (2006).
215. Archetti, M. Evolutionary game theory of growth factor production: implications for tumour heterogeneity and resistance to therapies. Br. J. Cancer 109, 1056-1062 (2013).
216. Basanta, D. et al. Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary game. Br. J. Cancer 106, 174-181 (2012).
217. Kianercy, A., Veltri, R. & Pienta, K. J. Critical transitions in a game theoretic model of tumour metabolism. Interface Focus 4, 20140014 (2014).
218. Basanta, D., Simon, M., Hatzikirou, H. & Deutsch, A. Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion. Cell Prolif. 41, 980-987 (2008).